Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 17

Showing 17 citing articles:

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents
Vivek Kumar, Jiyun Zhu, Balachandra Chenna, et al.
Journal of the American Chemical Society (2025)
Open Access
Addition to “The Death of the Strategy of Classical Chiral Switches Is an Exaggeration”
Israel Agranat, Ilaria D’Acquarica
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 344-346
Closed Access
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
A. Ravi Kumar, Haifa El Kilani, Alina Metzen, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Investigating the inhibition of benzimidazole derivatives on SARS-CoV-2 M pro by enzyme activity inhibition, spectroscopy, and molecular docking
Xueyuan Wang, Leyao Chen, Xiaoyu Chang, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-16
Closed Access
Research progress and perspectives of dual-target inhibitors
Xiaojing Pang, Wenyan Xu, Jing Liang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117453-117453
Closed Access
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Development of Acylhydrazone Linked Thiazoles as Non-Covalent Dual Inhibitors of SARS-CoV-2 Proteases
Vidya Jyothi Alli, Shubham Singh, Mounika Darna, et al.
European Journal of Medicinal Chemistry (2025), pp. 117509-117509
Closed Access
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19
Rongmeng Jiang, Bing Han, Wanhong Xu, et al.
NEJM Evidence (2024) Vol. 3, Iss. 6
Closed Access | Times Cited: 2
Applications of Molecular Docking Studies in SARS-CoV-2 Targeted Drug Discovery and the Gains Achieved through Molecular Docking
Merve Yildirim, İsmail Çeli̇k
Biomedical engineering (2024)
Open Access | Times Cited: 1
In vitro, in vivo, and in silico approaches for evaluating the preclinical DMPK profiles of ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor
Xiuqing Zhu, Yuexin Li, Huan Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease
Yahong Tan, Jinyue Yang, Min Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20258-20274
Closed Access
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
David W. Lin, M Armstrong, Jennifer Jiang, et al.
Medicinal chemistry reviews (2024), pp. 399-414
Closed Access
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
Hin Chu, Huiping Shuai, Jingxin Qiao, et al.
Research Square (Research Square) (2024)
Open Access
Multi‐Targeted Antivirals
Bing Ye, Letian Song, Meehyein Kim, et al.
(2024), pp. 405-421
Closed Access
Page 1

Scroll to top